Compare Inovio Pharmaceuticals Inc (INO) vs Quanta Services Inc (PWR) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

PWR (Quanta Services) trades at $639.20, up 1.7% with strong analyst support (75% buy ratings) and a consensus price target of $836.80. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Recent technical indicators are bearish despite oversold RSI readings, with key support at $613. The company benefits from AI infrastructure demand and utility spending, with a record $48B backlog.

Outlook is positive given exposure to grid modernization and AI data center build-out, but high valuation (P/E 86.77) and execution risks pose challenges. Earnings have consistently beaten estimates, with Q2 2026 results due July 30. Institutional sentiment is bullish, though technical weakness near-term warrants caution.